Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry.

Abstract:

BACKGROUND:Colorectal cancer (CRC) is a common malignancy. There is growing evidence that CRC incidence is increasing in the younger population. There is controversy surrounding the prognosis of young patients with CRC. In this study we reviewed Australian patients with metastatic CRC (mCRC) who were younger than 40 years of age at the time of diagnosis of metastatic disease. To our knowledge this is the first study to focus on this age group with mCRC. PATIENTS AND METHODS:This was a retrospective study using data from the South Australian Metastatic Colorectal Cancer database. We compared patient and disease characteristics, management approaches, and outcomes for age groups < 40 and ≥ 40. A multivariate Cox proportional hazards model was fitted to compare the survival outcomes (death from all causes) between the 2 groups. RESULTS:From 3318 patients, 46 (1.4%) were younger than 40 years of age. In a comparison of patients in the younger than 40-year-old group with the older group, a greater proportion had synchronous metastatic disease (80.4% vs. 64.4%, respectively; P = .04) and disease originating from the left colon (71.7% vs. 61.7%, respectively; P = .035); also a larger proportion in the younger than 40-year-old group received chemotherapy compared with the older group (82.6% vs. 58.7%, respectively; P < .01). In the adjusted multivariate model, survival was not significantly different between the 2 groups (hazard ratio, 0.81; 95% confidence interval, 0.56-1.16; log rank P = .25). CONCLUSION:Young-onset mCRC patients, when defined as aged younger than 40 years, have equivalent survival compared with their older counterparts. This is despite differences in disease characteristics and management approach between the 2 groups.

journal_name

Clin Colorectal Cancer

authors

Vatandoust S,Price TJ,Ullah S,Roy AC,Beeke C,Young JP,Townsend A,Padbury R,Roder D,Karapetis CS

doi

10.1016/j.clcc.2015.07.005

subject

Has Abstract

pub_date

2016-03-01 00:00:00

pages

32-6

issue

1

eissn

1533-0028

issn

1938-0674

pii

S1533-0028(15)00096-1

journal_volume

15

pub_type

杂志文章
  • Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.

    abstract:BACKGROUND:Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies. Their real-life evaluation is insufficient, especially in elderly and frail patients. The aim was to describe use, safety, and effectiveness of targeted therapies in first-line mCRC treatment according to age. PATIENTS AND...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.11.005

    authors: Gouverneur A,Coutureau J,Jové J,Rouyer M,Grelaud A,Duc S,Gérard S,Smith D,Ravaud A,Droz C,Bernard MA,Lassalle R,Forrier-Réglat A,Noize P,ETNA study group and the EREBUS study group.

    更新日期:2019-03-01 00:00:00

  • Laparoscopic radical correction combined with extensive lymphadenectomy and pelvic autonomic nerve preservation for mid-to-low rectal cancer.

    abstract:OBJECTIVE:The purposes of this study were to confirm the definite metastasis and micrometastasis rate of upward and lateral lymph nodes of mid-to-low rectal cancer at stage II and stage III, and to evaluate the feasibility and safety of laparoscopic radical correction combined with extensive lymphadenectomy and pelvic ...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2011.03.025

    authors: Liu T,Zhang C,Yu P,Chen J,Zeng D,Gan L,Lv W,Liu L,Yan X

    更新日期:2011-09-01 00:00:00

  • COVID-19 and the Global Impact on Colorectal Practice and Surgery.

    abstract:BACKGROUND:The novel severe acute respiratory syndrome coronavirus 2 virus that emerged in December 2019 causing coronavirus disease 2019 (COVID-19) has led to the sudden national reorganization of health care systems and changes in the delivery of health care globally. The purpose of our study was to use a survey to a...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2020.05.011

    authors: Nunoo-Mensah JW,Rizk M,Caushaj PF,Giordano P,Fortunato R,Dulskas A,Bugra D,da Costa Pereira JM,Escalante R,Koda K,Samalavicius NE,Maeda K,Chun HK,ISUCRS COVID-19 Participating Investigator Group.

    更新日期:2020-09-01 00:00:00

  • Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.

    abstract::Modern chemotherapy combinations for metastatic colorectal cancer (mCRC) comprise infusional 5-fluorouracil (5-FU), leucovorin, and irinotecan or oxaliplatin. The fluoropyrimidine derivative capecitabine is at least as effective as 5-FU plus leucovorin bolus regimens. It displays a favorable toxicity profile and offer...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2008.n.015

    authors: Moosmann N,Heinemann V

    更新日期:2008-03-01 00:00:00

  • Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value?

    abstract::As new improvements in the treatment of colorectal cancer have become available, it has become important to understand the benefits of new therapies or the deleterious effects stemming from the increased risk of toxicity. In particular, a more rational approach to adjuvant chemotherapy for patients with stage II/III d...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/ccc.2006.n.019

    authors: Funaioli C,Pinto C,Mutri V,Di Fabio F,Ceccarelli C,Martoni AA

    更新日期:2006-05-01 00:00:00

  • Is levoleucovorin an alternative to racemic leucovorin? A literature review.

    abstract:PURPOSE:Our purpose is to perform a comprehensive literature review of the use of levoleucovorin in gastrointestinal malignancies and to assess whether levoleucovorin is a reasonable alternative to racemic leucovorin. DESIGN:This is an extensive literature review of levoleucovorin use in patients with gastrointestinal...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2009.n.034

    authors: Kovoor PA,Karim SM,Marshall JL

    更新日期:2009-10-01 00:00:00

  • Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer.

    abstract:BACKGROUND:We performed a meta-analysis of previous reports evaluating the effect of mFIO (modified FOLFIRINOX; leucovorin, 5-fluorouracil, irinotecan, oxaliplatin) regimens in advanced pancreatic cancer. MATERIALS AND METHODS:We performed a meta-analysis of reported studies in PubMed, Scopus, and Web of Science (1950...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clcc.2018.03.007

    authors: Usón Junior PLS,Rother ET,Maluf FC,Bugano DDG

    更新日期:2018-09-01 00:00:00

  • Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.

    abstract::The discovery of the key role of the epidermal growth factor receptor (EGFR) and its downstream signaling effectors in the pathophysiology of colorectal cancer (CRC) has ushered in the clinical use of targeted therapies in the treatment of metastatic CRC (mCRC). The anti-EGFR monoclonal antibodies cetuximab and panitu...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clcc.2015.05.006

    authors: Lee MS,Kopetz S

    更新日期:2015-12-01 00:00:00

  • Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy.

    abstract::Primary squamous cell colorectal carcinomas are uncommon, and their characteristics are not well known. They seem to occur most commonly in the fifth decade of life with a slight predominance for men. The most commonly reported anatomic locations are the rectum and the proximal colon. Clinical features and common diag...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2001.n.006

    authors: Copur S,Ledakis P,Novinski D,Mleczko KL,Frankforter S,Bolton M,Fruehling RM,VanWie E,Norvell M,Muhvic J

    更新日期:2001-05-01 00:00:00

  • Prognostic Effect of Tumor Sidedness in Colorectal Cancer: A SEER-Based Analysis.

    abstract:BACKGROUND:The prognostic value of tumor sidedness in metastatic colorectal cancer (CRC) has been established, but its impact on nonmetastatic disease remains unclear. Our study aimed to explore the prognostic effect of tumor sidedness by subgroup survival analyses, according to histology and tumor grade in stage I-IV ...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.10.005

    authors: Li Y,Feng Y,Dai W,Li Q,Cai S,Peng J

    更新日期:2019-03-01 00:00:00

  • Real-World Effect of Maintenance and Intermittent Chemotherapy on Survival in Metastatic Colorectal Cancer.

    abstract:BACKGROUND:With improved survival and longer duration of treatment, clinicians managing metastatic colorectal cancer (mCRC) increasingly consider intermittent (IC) or maintenance chemotherapy (MC), but the effect of these treatment modifications on real-world outcomes is unclear. PATIENTS AND METHODS:Using a populatio...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2017.10.011

    authors: Loree JM,Tan SK,Lafond LM,Speers CH,Kennecke HF,Cheung WY

    更新日期:2018-03-01 00:00:00

  • Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.

    abstract:BACKGROUND:As of 2006, bevacizumab was available for the treatment of metastatic colorectal cancer (mCRC) in British Columbia (BC). This study compares survival between referred patients diagnosed with mCRC in 2003/2004 (pre-bevacizumab era) and 2006 (bevacizumab era). PATIENTS AND METHODS:The BC cancer agency (BCCA) ...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2011.03.004

    authors: Renouf DJ,Lim HJ,Speers C,Villa D,Gill S,Blanke CD,O'Reilly SE,Kennecke H

    更新日期:2011-06-01 00:00:00

  • Spindle Assembly Checkpoint as a Potential Target in Colorectal Cancer: Current Status and Future Perspectives.

    abstract::Colorectal cancer (CRC), one of the most common malignancies worldwide, is often diagnosed at an advanced stage, and resistance to chemotherapeutic and existing targeted therapy is a major obstacle to its successful treatment. New targets that offer alternative clinical options are therefore urgently needed. Recently,...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clcc.2016.06.006

    authors: Diogo V,Teixeira J,Silva PM,Bousbaa H

    更新日期:2017-03-01 00:00:00

  • Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.

    abstract:BACKGROUND:Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-r...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.08.002

    authors: Sunakawa Y,Yang D,Cao S,Zhang W,Moran M,Astrow SH,Hsiang J,Stephens C,Tsuji A,Takahashi T,Tanioka H,Negoro Y,Takagane A,Tani S,Yamaguchi T,Eto T,Fujii M,Ichikawa W,Lenz HJ

    更新日期:2018-12-01 00:00:00

  • Local excision for rectal carcinoma.

    abstract::Local excision is an alternative approach to radical proctectomy for rectal cancer, but from an oncologic standpoint, it is a compromise, and its role remains controversial. Careful patient selection is essential because local excision is generally considered only for early rectal cancer with no evidence of nodal meta...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2008.n.050

    authors: Kim E,Hwang JM,Garcia-Aguilar J

    更新日期:2008-11-01 00:00:00

  • A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer.

    abstract:INTRODUCTION:The aim of this study was to evaluate the efficacy and safety of maintenance therapy with axitinib versus placebo following induction therapy in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS:In this double-blinded, phase II trial, patients with mCRC who had not progressed after 6...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clcc.2018.02.004

    authors: Grávalos C,Carrato A,Tobeña M,Rodriguez-Garrote M,Soler G,Vieitez JM,Robles L,Valladares-Ayerbes M,Polo E,Limón ML,Safont MJ,Martínez de Castro E,García-Alfonso P,Aranda E,Spanish Cooperative Group for the Treatment of Digest

    更新日期:2018-06-01 00:00:00

  • Conversion to Resection in Patients Receiving Systemic Chemotherapy for Unresectable and/or Metastatic Colorectal Cancer-Predictive Factors and Prognosis.

    abstract:BACKGROUND:Systemic chemotherapy increases the possibility of resection in patients with initially unresectable colorectal cancer (CRC), especially patients with hepatic metastasis. However, the predictive factors and prognosis of conversion to resection after chemotherapy in patients with various organ metastases rema...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2017.10.002

    authors: Nozawa H,Ishihara S,Kawai K,Hata K,Kiyomatsu T,Tanaka T,Nishikawa T,Otani K,Yasuda K,Sasaki K,Kaneko M,Murono K

    更新日期:2018-03-01 00:00:00

  • A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.

    abstract:PURPOSE:Capecitabine has shown similar efficacy to 5-fluorouracil (5-FU); a regimen containing 2 weeks of capecitabine/oxaliplatin (CapOx) has demonstrated noninferiority to infusional 5-FU/oxaliplatin/leucovorin (FOLFOX) for the treatment of metastatic colorectal cancer (mCRC). This phase II study explores the efficac...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2010.n.021

    authors: Lubner SJ,Loconte NK,Holen KD,Schelman W,Thomas JP,Jumonville A,Eickhoff JC,Seo S,Mulkerin DL

    更新日期:2010-07-01 00:00:00

  • Thymidylate synthase: a critical target for cancer chemotherapy.

    abstract::Thymidylate synthase (TS) is a key enzyme in the synthesis of 2'-deoxythymidine-5'-monophosphate, an essential precursor for DNA biosynthesis. For this reason, this enzyme is a critical target in cancer chemotherapy. As the first TS inhibitor in clinical use, 5-fluorouracil (5-FU) remains widely used for the treatment...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2002.n.003

    authors: Rose MG,Farrell MP,Schmitz JC

    更新日期:2002-02-01 00:00:00

  • Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases.

    abstract::The development of brain metastases originating from colorectal cancer (CRC) is an infrequent phenomenon occurring in < 5% of patients. Yet, it is feasible that physicians will be diagnosing more patients with brain metastases because of the prolonged survival in our current patient population. The anti-angiogenic age...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2008.n.010

    authors: Bhaskara A,Eng C

    更新日期:2008-01-01 00:00:00

  • Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.

    abstract:BACKGROUND:The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation (ICECREAM) study assessed the efficacy of cetuximab monotherapy compared with cetuximab combined with chemotherapy for quadruple wild-type (KRAS, NRAS, BRAF, or P13KCA exon 20) metastatic colorectal cancer. PATIENTS AND METHODS:Patients w...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clcc.2018.06.002

    authors: Shapiro JD,Thavaneswaran S,Underhill CR,Robledo KP,Karapetis CS,Day FL,Nott LM,Jefford M,Chantrill LA,Pavlakis N,Tebbutt NC,Price TJ,Khasraw M,Van Hazel GA,Waring PM,Tejpar S,Simes J,Gebski VJ,Desai J,Segelov E

    更新日期:2018-12-01 00:00:00

  • Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016.

    abstract:BACKGROUND:Anal squamous cell carcinoma (ASCC) is a rare, human papilloma virus-associated cancer. The purpose was to investigate the population-based incidence rates, age and gender distribution, and survival of ASCC. MATERIALS AND METHODS:All primary ASCC in 1987 to 2016 were identified in the Cancer Registry of Nor...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.10.001

    authors: Guren MG,Aagnes B,Nygård M,Dahl O,Møller B

    更新日期:2019-03-01 00:00:00

  • Significance of PITX2 Promoter Methylation in Colorectal Carcinoma Prognosis.

    abstract:BACKGROUND:New treatment modalities and a growing understanding of the complex genetic tumor landscape have improved the outcome of colorectal cancer (CRC) patients. Nonetheless, more individualized treatment regimens, taking individual tumor characteristics into account, have been recently postulated and prognostic bi...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.02.008

    authors: Semaan A,Uhl B,Branchi V,Lingohr P,Bootz F,Kristiansen G,Kalff JC,Matthaei H,Pantelis D,Dietrich D

    更新日期:2018-06-01 00:00:00

  • Circulating endothelial cells and their subpopulations: role as predictive biomarkers in antiangiogenic therapy for colorectal cancer.

    abstract::Several anticancer therapies have been developed to block angiogenesis, a key mechanism in tumor growth and metastasis. The predominantly cytostatic action of these compounds makes an assessment of their clinical activities inadequate if based only on the reduction of the tumor dimensions, as this may not reflect thei...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clcc.2014.12.002

    authors: Manzoni M,Comolli G,Torchio M,Mazzini G,Danova M

    更新日期:2015-03-01 00:00:00

  • Outcome of Molecular Targeted Agents Plus Chemotherapy for Second-Line Therapy of Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Trials.

    abstract:INTRODUCTION:The aim of this study was to evaluate the efficacy and toxicity of molecular targeted agents plus chemotherapy compared with chemotherapy alone as second-line therapy for patients with metastatic colorectal cancer (mCRC). MATERIALS AND METHODS:We identified randomized controlled trials that compared molec...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clcc.2016.03.005

    authors: Pei X,Liu Y,Sun L,Zhang J,Fang Y,Liao X,Liu J,Zhang C,Yin T

    更新日期:2016-12-01 00:00:00

  • Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.

    abstract:INTRODUCTION:Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU. Given the additional benefit of oxaliplatin over FP alone in the management of color...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.09.006

    authors: Chakrabarti S,Sara J,Lobo R,Eiring R,Finnes H,Mitchell J,Hartgers M,Okano A,Halfdanarson T,Grothey A

    更新日期:2019-03-01 00:00:00

  • Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer.

    abstract:BACKGROUND:Initial treatment with either neoadjuvant chemoradiation (CRT) or induction FOLFOX (5-Fluorouracil, leucovorin, and oxaliplatin) chemotherapy followed by CRT is considered standard treatment for locally advanced rectal cancer. We compared patient-reported outcomes (PRO) during CRT in patients who had receive...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2019.04.001

    authors: Ng SY,Colborn KL,Cambridge L,Cercek A,Reidy-Lagunes DL,Segal N,Stadler Z,Saltz LB,Paty PB,Guillem J,Weiser MR,Nash G,Garcia-Aguilar J,Goodman KA

    更新日期:2019-09-01 00:00:00

  • Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications.

    abstract:BACKGROUND:Gemcitabine-related pneumonitis (GRP) has been reported relatively frequently for pancreas cancer in the literature; however, underlying risk factors and optimal management remain to be defined. We studied a cohort of patients with GRP and investigated potential predisposing factors in pancreatic cancer pati...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2015.08.003

    authors: Sahin IH,Geyer AI,Kelly DW,O'Reilly EM

    更新日期:2016-03-01 00:00:00

  • Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer.

    abstract::Bevacizumab is a humanized monoclonal antibody approved by the US Food and Drug Administration for use in combination with fluorouracil (FU)-based chemotherapy for first-line treatment of patients with metastatic colorectal carcinoma (CRC). Its mechanism of action is inhibition of tumor angiogenesis by neutralizing va...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2010.n.008

    authors: Gamboa EO,Rehmus EH,Haller N

    更新日期:2010-01-01 00:00:00

  • Rising Proportion of Young Individuals With Rectal and Colon Cancer.

    abstract:BACKGROUND:Recent trends have identified increasing number of young individuals with rectal and colon cancers. These individuals, who are younger than 50 years old, in most instances would not meet screening guidelines. We aimed to report the characteristics and trend of the rising proportion of young individuals being...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.10.002

    authors: Kasi PM,Shahjehan F,Cochuyt JJ,Li Z,Colibaseanu DT,Merchea A

    更新日期:2019-03-01 00:00:00